Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies

A highly concentrated (20%) immunoglobulin (Ig)G preparation for subcutaneous administration (IGSC 20%), would offer a new option for antibody replacement therapy in patients with primary immunodeficiency diseases (PIDD). The efficacy, safety, tolerability and pharmacokinetics of IGSC 20% were evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Borte, M., Kriván, G., Derfalvi, B., Maródi, L., Harrer, T., Jolles, S., Bourgeois, C., Engl, W., Leibl, H., McCoy, B., Gelmont, D., Yel, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167020/
https://www.ncbi.nlm.nih.gov/pubmed/27613250
http://dx.doi.org/10.1111/cei.12866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167020/
https://www.ncbi.nlm.nih.gov/pubmed/27613250
http://dx.doi.org/10.1111/cei.12866

Ejemplares similares